Endo S, Imai H, Mouri A, Tsukamoto K, et al. Efficacy and safety of first-line nivolumab plus ipilimumab treatment in elderly patients (aged >/= 75 years) with non-small cell lung cancer. J Cancer Res Clin Oncol 2025;151:43.
PMID: 39843575